Company Overview and News
EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board of Directors, effective September 18, 2018.
ABT SAGE INVVY IDRAW JUNO IDRA VNDA IZQVF ABT
2018-09-07 seekingalpha - 3
Discussion: On September 4, Recro Pharma (REPH) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the company now plans to submit a revised NDA by the end of this month. Suggestions offered by the FDA now guides the company to include revised labelling language and further information on extractable and leachable items.
DOVA MNKD SYBX TSRO REDIF AST OPK RDHL PBYI ZGNX SNGX DVAX ADRO ALXN BIIB AGLE EIGR HZNP EYEG HSDT CHEK EYEGW SNY BCRX SAGE REPH JNJ UTHR APLS
It has been about a month since the last earnings report for Ligand Pharmaceuticals (LGND - Free Report) . Shares have added about 4.6% in that time frame, outperforming the S&P 500.
SAGE LGNZZ ALDX SPPI LGND LGNYZ LGNXZ LGNDZ
The following slide deck was published by Sage Therapeutics in conjunction with their 2018 Q2 earnings call.
Good morning, and welcome to Sage Therapeutics' Second Quarter 2018 Financial Results Conference Call. [Operator Instructions]. This call is being webcast live on the Investors & Media section of Sage's website at sagerx.com. This call is a property of Sage Therapeutics and recordings, reproductions or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited.
2018-08-07 zacks - 1
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported second-quarter 2018 adjusted earnings of $2.59 per share, significantly up from the year-ago figure of 67 cents. The bottom line also beat the Zacks Consensus Estimate of 93 cents.
SAGE AMGN SPPI LGNZZ ALDX LGND LGNYZ NVS LGNXZ LGNDZ WXXWY
sage-10q_20180630.htm UNITED STATES
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-07-26 investorplace - 2
Now more than ever, it makes sense to listen to analysts with a proven track record of success. Anyone can claim to be a market expert. Anyone can have an opinion. But that opinion becomes a lot more meaningful when the figures show that this person tends to be right.
LOW DB MCHP SAGE WFM BABA AMZN IMMU MU GPOR NTR MS UNH
Over the years there have been questions surrounding the efficacy of some medications used to treat mental health issues. Last year a Harvard professor argued on CBS’ 60 Minutes that there was little difference between a psychiatric drug and a placebo.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to SAGE / Sage Therapeutics, Inc. on message board site Silicon Investor.
as of ET